Argus
•
Sep 02, 2026
PEN: Lowering target price to $355.00
Summary
Domiciled in the US, Penumbra designs, manufactures, and markets an array of thrombectomy and embolization devices and equipment to mechanically remove blood clots.
Upgrade to begin using premium research reports and get so much more.
Exclusive reports, detailed company profiles, and best-in-class trade insights to take your portfolio to the next level
UpgradeRelated Reports
GMED: Lowering target price to $89.00
Sep 02, 2026
•
GMED
TFX: Raising target price to $148.00
Sep 02, 2026
•
TFX
HAE: Lowering target price to $107.00
Sep 02, 2026
•
HAE
MEDP: Lowering target price to $642.00
Sep 02, 2026
•
MEDP
PCTY: Raising target price to $172.00
Sep 02, 2026
•
PCTY
